RHHBF OTC
Credit Risk of going bust: lower than 62% of companies Debt: 9.2% of company value Bonds: none of note held by US funds details ▾
Total debt $38.17B against a stock market value of $378.38B.
Distance to default 6.51 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $23.04B (short-term plus half of long-term), stock volatility 45.6%; Altman Z'' 4.15. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Basel, BS 4070
CH
Founded in 1896 and headquartered in Basel, Switzerland, Roche Holding AG is a global enterprise active in both the pharmaceutical and diagnostics sectors. Its extensive operations cover numerous countries, including Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium, alongside other international markets. The company's pharmaceutical division develops and provides therapies addressing a broad spectrum of medical conditions. These include cancer (oncology), neurological disorders, infectious diseases, immunological conditions, cardiovascular and metabolic issues, ophthalmological ailments, and respiratory illnesses. Furthermore, its product portfolio extends to treatments for anemia, dermatological problems, hemophilia, inflammatory and autoimmune diseases, and conditions related to organ transplantation. Within its diagnostics business, Roche provides a range of in vitro tests designed for identifying various diseases, such as cancer, diabetes, COVID-19, hepatitis, and human papillomavirus, among others. Complementing this, it also furnishes essential diagnostic instruments and chemical reagents. A significant research collaboration is in place with Synlogic, Inc., aimed at discovering a novel synthetic biotic treatment for inflammatory bowel disease (IBD).